XBiotech (NASDAQ: XBIT) announced today the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE